SCHEMBL5863676

SCHEMBL5863676

Nc1cnc2c(c1)C(=O)NCC2

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 6/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
PLK1 P53350 1/20 0.40
CCNA1 P78396 1/20 0.40
PARP1 P09874 7/20 0.40
MAPK1 P28482 1/20 0.40
MAPKAPK2 P49137 1/20 0.40
PDE4B Q07343 1/20 0.39
PARP10 Q53GL7 7/20 0.37
PARP11 Q9NR21 3/20 0.37
PDPK1 O15530 1/20 0.37
F7 P08709 1/20 0.37
F3 P13726 1/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31553851 1.00 CDC7 (0.40) CDC7CCNA2CDK2CDK9PLK1
SCHEMBL31553914 0.90 CDC7 (0.38) CDC7CCNA2CDK2CDK9PLK1
SCHEMBL25323349 0.82 PARP16 (0.38) CDC7CCNA2CDK2CDK9PLK1
SCHEMBL30551099 0.82 PARP16 (0.38) CDC7CCNA2CDK2CDK9PLK1
SCHEMBL25925662 0.79 PARP10 (0.37) CDC7CCNA2CDK2CDK9PLK1
SCHEMBL30285326 0.79 PARP10 (0.51) CDC7CDK2CDK9PLK1PARP1
SCHEMBL5863725 0.79 PARP10 (0.51) CDC7CDK2CDK9PLK1PARP1
SCHEMBL12457586 0.79 PARP10 (0.51) CDC7PARP1PARP10PARP11PDPK1
SCHEMBL9998692 0.76 PARP10 (0.55) CDC7PARP1MAPKAPK2PARP10PARP11
SCHEMBL10314912 0.76 PKN1 (0.39) CDC7PARP1PARP10PARP11PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC CDC7 2903/4885CCNA2 1459/4885CDK2 2059/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN CDC7 3378/4885CCNA2 163/4885CDK2 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.